Vantage logo

Big pharma spinouts grow up

Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.

Vantage logo

Albireo comes up to IBAT in Nash

Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.